Last updated on February 2019

Phase I/II Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH


Brief description of study

Open-label, dose-escalation clinical trial of scAAV9.U1a.hSGSH injected intravenously through a peripheral limb vein

Detailed Study Description

Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein. The vector will be delivered undiluted over 5 to 50 minutes, under light to moderate sedation as needed. Dosing volume will be approximately 0.5 to 3 mL/kg, depending on final vector product concentration and subject cohort. A tapering course of prophylactic enteral prednisone or prednisolone will be administered

Clinical Study Identifier: NCT02716246

Find a site near you

Start Over

Women's and Children's Hospital

North Adelaide, Australia
7.89miles
  Connect »